Nanoscope Therapeutics
Nanoscope Therapeutics, a gene therapy company, uses light-sensitive molecules to treat retinal degenerative diseases and restore vision.
Founded
2017Nanoscope Therapeutics, a gene therapy company, uses light-sensitive molecules to treat retinal degenerative diseases and restore vision.
Nanoscope Therapeutics, founded to address the unmet needs of individuals with retinal degenerative diseases, focuses on pioneering gene therapies using ambient light-sensitive molecules. Their core mission is to restore vision in patients suffering from conditions like Retinitis Pigmentosa, Stargardt disease, and dry AMD. By leveraging proprietary optogenetic therapy, Nanoscope aims to provide a transformative solution for millions of people who currently have no curative options.
Notable figures affiliated with Nanoscope Therapeutics include leading scientists and clinicians in the field of gene therapy and ophthalmology. The company has secured significant investments from prominent venture capital firms and has made substantial progress in clinical trials, such as the STARLIGHT and RESTORE trials. These achievements underscore their potential impact on the field of vision restoration, offering renewed hope and improved quality of life for patients worldwide.
Companies similar to Nanoscope Therapeutics include Nanoscope Technologies, Oculogenex, Atsena Therapeutics and EyeCyte.
Nanoscope Therapeutics was founded in 2017.
Nanoscope Therapeutics' headquarters is located in Bedford, TX, US.
Nanoscope Therapeutics' most recent funding round was for $1.5M (USD) in September 2021.
As of Sep 14, 2021, Nanoscope Therapeutics has raised a total of $3.5M (USD).
Nanoscope Therapeutics has 28 employees as of Feb 5, 2024.
Atsena Therapeutics
atsenatx.com
